2024 Mid-Year Update

The Directors of Inizio are pleased to present a mid-year update for 2024.

Inizio is a pharmaceutical commercialization partner, offering a complete suite of best-in-class and innovative scientific, medical, marketing, advisory, communications and patient engagement services through our 10,500 experts across 50 countries. We provide tailored, data-driven & technology-enabled solutions to Life Science Companies that help them to navigate the commercialisation journey to optimise their Product Development, Marketing and Reach, maximising patient access.

We have partnered on 1,200 assets across all therapeutic areas in the past two years with a significant proportion of these assets serving patients in the most innovative areas of medicine. Furthermore, we are a product launch powerhouse, helping our clients successfully plan and execute launch activity – in the past two years Inizio has supported 50% of all US product launches of new innovative medicines, many of which are projected to be market leaders in terms of commercial performance and patient need. Unlocking this value from our scaled platform for our clients and all patients is a strategic imperative, and we remain focussed on the areas of greatest need, value and innovation.

Trading performance from our businesses continues to be robust, reflecting solid market fundamentals and the critical nature of the services we offer. While revenues for the first half of 2024 declined compared to the prior year, this reflects an exceptionally strong trading performance in the first half of 2023; and despite the revenue performance this year, Group margins have increased year on year. We continue to expand our client base, supported by robust growth in the pharmaceutical and biotech sectors.

The Group continues to trade in line with and remains comfortably compliant with the terms of its debt facilities. We are well placed to deliver strong trading performance in the second half of the year and to continue to achieve our growth strategy across the company.